ライフサイエンスコーパス: von Willebrand factor

1 4, CD45) and endothelial markers (CD31, vWf, von Willebrand factor).

2 nducible factor-1 alpha), survivin, and VWF (Von Willebrand factor).

3 d bleeding tendency), without differences in von Willebrand factor.

4 nd secretion (platelet function markers) and von Willebrand factor.

5 ts only at the ABO locus for factor VIII and von Willebrand factor.

6 on in controls, most notably factor VIII and von Willebrand factor.

7 rombocytopathy, counterbalanced by increased von Willebrand factor.

8 glycation end products (3.5 [1.7-7.2]), and von Willebrand Factor (3.1 [2.0-5.2]).

9 With a von Willebrand factor A (VWA) domain and six thrombospon

10 ture similar to integrin beta-chains, with a von Willebrand factor A domain containing a functional m

11 ific humoral autoimmune response against the von Willebrand factor A domain-containing protein 5a, an

12 racting with AAA+ ATPase (ViaA) containing a von Willebrand Factor A domain.

13 This mechanism may apply to other von Willebrand factor A domains undergoing large conform

14 haI domains of integrin are the best-studied von Willebrand factor A domains undergoing significant c

15 lost for alpha2delta-1 with mutations in the von-Willebrand-factor-A domain.

16 ble model with %TBSA, inhalation injury, and von Willebrand factor-A2 had comparable discrimination t

17 With the exception of von Willebrand factor, all the above changes correlated

18 a/SU5416 mouse model identified the presence von Willebrand factor/alpha-smooth muscle actin-positive

19 Von Willebrand factor, an ultralarge concatemeric blood

20 have been previously associated with plasma von Willebrand factor and coagulation factor VIII levels

21 Increase in fibrinogen, factor VIII, and von Willebrand factor and decrease in antithrombin III c

22 Patients with severe CAV had raised serum von Willebrand factor and decreased serum thrombomodulin

23 s (WPBs) are secretory granules that contain von Willebrand factor and P-selectin, molecules that reg

24 histamine-evoked secretion of the WPB cargos von Willebrand factor and P-selectin.

25 % was observed in the alpha-granule proteins von Willebrand factor and P-selectin.

26 growth of microthrombi that are composed of von Willebrand factor and platelets, which account for t

27 Basal plasma levels of von Willebrand factor and recruitment of platelets to th

28 ich remain anchored to the vascular wall via von Willebrand factor and reveal significant neutrophil

29 e tyrosine kinase decreased more quickly and von Willebrand factor and thrombomodulin decreased more

30 equires two additional serum factors, namely von Willebrand factor and thrombospondin-1.

31 he PVN, driven partly by endothelial-derived von Willebrand factor and vascular cell adhesion molecul

32 eaves the pro-thrombotic and proinflammatory von Willebrand factor) and presence of neutrophil extrac

33 ogenic mimicry (VM), the mature vasculature (von Willebrand Factor) and tumor induced angiogenesis (b

34 lta-like protein 4), CLDN5 (claudin-5), VWF (von Willebrand factor), and CDH5 (VE-cadherin).

35 of angiopoietin-2, angiopoietin-2/-1 ratio, von Willebrand factor, and endocan were indicative of co

36 g in affinity, dependence on separation from von Willebrand factor, and mediation by the C2 domain.

37 ndothelial injury, including angiopoietin-2, von Willebrand Factor, and soluble thrombomodulin.

38 dothelial growth factor receptor 2], or VWF [von Willebrand Factor]), and tube-like formation.

39 was assessed at admission on plasma samples (von Willebrand factor, angiopoietin-1 and angiopoietin-2

40 controls, increased levels of calprotectin, von Willebrand factor, angiotensinogen, IL8, IL15, IP10,

41 s have determined that age, body mass index, von Willebrand factor antigen (VWF:Ag) levels, and ABO b

42 sed postoperative portal venous pressure and von Willebrand factor antigen levels as a marker for int

43 EST PRACTICE ADVICE 9: Desmopressin releases von Willebrand factor as its primary hemostatic mechanis

44 With the exception of von Willebrand factor, assessed with the median cutoff m

45 Adjustment for factor VIII or von Willebrand factor attenuated these odds ratios, indi

46 Fn deposition was independent of fibrinogen, von Willebrand factor, beta3 integrin, and platelets.

47 inants (IsdA and IsdB), coagulase (Coa), and von Willebrand factor binding protein (vWbp)-are dispens

48 ach assigns this association to the ADAMTS13 von Willebrand factor-binding domain (P=1.2x10(-4)).

49 ve protein) and endothelial cell activation (von Willebrand factor) both at baseline and during follo

50 ns in D-dimer by 24% (95% CI, -30% to -18%), von Willebrand factor by 22% (95% CI, -35% to -9%), thro

51 extracellular proteins, among which are many von Willebrand factor C (vWC) domain-containing proteins

52 th factors bind to both an N- and C-terminal von Willebrand factor C domain of chordin.

53 d by the co-injection of mRNA coding for the von Willebrand factor C domain of collagen IIalpha1a, in

54 lial cell and junctional proteins, including von Willebrand factor, CD31, occludin, and vascular endo

55 II ranges from 15 to 19 hours because of the von Willebrand factor chaperone effect.

56 (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows

57 din type 1 repeats, member 13), the specific von Willebrand factor-cleaving protease.

58 r, we focus on emerging data suggesting that von Willebrand factor, coagulation cascade activation, a

59 Also, when whole blood was perfused in von Willebrand factor-coated microfluidic channels, plat

60 ble model with %TBSA, inhalation injury, and von Willebrand factor could be used to better identify a

61 of high molecular weight (HMW) multimers of von Willebrand factor defect could be instantaneous afte

62 th microbubbles targeted to the A1 domain of von Willebrand factor demonstrated selective signal enha

63 As both integrins and MUC5AC have a von Willebrand factor domain, we assessed for possible i

64 in synaptogenic domain and the alpha2delta-1 von-Willebrand-factor domain.

65 omain 2, vascular endothelial growth factor, von Willebrand factor, E-selectin, intercellular adhesio

66 th factor, soluble fms-like tyrosine kinase, von Willebrand factor, E-selectin, intercellular adhesio

67 clerotic plaque formation involving enhanced von Willebrand factor exposure on endothelial cells and

68 ency was associated with reduced endothelial von Willebrand factor expression, which has been shown t

69 function, fibrin(ogen) deposition, and VWF (von Willebrand factor) expression in brain vessels and V

70 ging, we simultaneously monitored reversible Von Willebrand factor extension and binding to GPIbalpha

71 Replacement therapy with plasma-derived von Willebrand factor-factor VIII concentrates represent

72 y components of the thrombus itself, such as von Willebrand factor, fibrinogen, and thrombocytes.

73 Here we report that, under flow, von Willebrand factor/glycoprotein Ibalpha-dependent pla

74 d with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitor

75 Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain i

76 Caplacizumab, an anti-von Willebrand factor humanized, bivalent variable-domai

77 n log-transformed levels of the A2 domain of von Willebrand factor in the first 24 hours was most str

78 ogether with that of the endothelial marker, von Willebrand factor, in human and rat liver tissue, at

79 tissue inhibitor of metalloproteinase 2, and von Willebrand factor-in plasma samples from 611 patient

80 ge and apoptosis (release of fractalkine and von Willebrand factor; increased caspase 3 expression).

81 Re-compaction of Von Willebrand factor is accelerated by intramolecular i

82 We show that Von Willebrand factor is activated through a two-step co

83 Von Willebrand factor is proposed to be mechanically act

84 alth of clotting factor VIII, factor IX, and Von Willebrand Factor knockout (FVIII(-/-), FIX(-/-), an

85 teractions are in part caused by endothelial von Willebrand factor large multimers, which can be reve

86 L for the <1st eGFR percentile category) and von Willebrand factor levels (adjusted mean difference,

87 In an independent cohort, we found higher von Willebrand factor levels and equivalent propeptide l

88 istal tubular cytokeratin 7, and endothelial von Willebrand factor markers.

89 ding apolipoprotein A-I, thrombomodulin, and von Willebrand factor, may contribute to vascular diseas

90 activation of unactivated platelets through von Willebrand-factor-mediated processes allowed greater

91 recombinant ADAMTS13 eliminated platelet and von Willebrand factor molecular imaging signal.

92 These results demonstrate that variations in von Willebrand factor multimeric pattern are highly dyna

93 l cells (ECs) synthesize, store, and secrete von Willebrand factor multimeric strings and coagulation

94 inhibits the interaction between ultralarge von Willebrand factor multimers and platelets.

95 bulin fragment, inhibits interaction between von Willebrand factor multimers and platelets.

96 ts, no aHUS patients demonstrated ultralarge von Willebrand factor multimers at presentation.

97 ecreased proportion of high-molecular-weight von Willebrand factor multimers could reduce platelet ad

98 ase ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microth

99 von Willebrand factor multimers were abnormal in 1 of 26

100 ample for such a key component as it cleaves von Willebrand factor multimers, reduces platelet adhesi

101 ed by aggregation of platelets on ultralarge von Willebrand factor multimers.

102 ceptors on the platelet surface binding with von Willebrand factor on the vascular walls.

103 in high-molecular-weight (HMW) multimers of von Willebrand factor or point-of-care assessment of hem

104 d with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII.

105 r with its binding to phospholipid surfaces, von Willebrand factor, or other components of the intrin

106 teractions, increased endothelial-associated von Willebrand factor, particularly in a multimerized fo

107 huPAD4 in vivo induces the formation of VWF (von Willebrand factor)-platelet strings in mesenteric ve

108 EDE levels of VCAM-1, von Willebrand factor, platelet-derived growth factor (P

109 apse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten pla

110 latelet buds containing incorrect numbers of von Willebrand factor-positive granules.

111 therlands (WiN) study by using the ratios of von Willebrand factor propeptide (VWFpp) or factor VIII

112 The ratios between von Willebrand factor propeptide (VWFpp) or factor VIII

113 otein-cleaving enzymes (ADAMTS7 and 12), the von-Willebrand Factor proteinase (ADAMTS13) and a group

114 -0.3, P < 0.01) or endothelial injury marker von Willebrand factor (R = +0.3; P < 0.01).

115 ceptor complex GPVI-FcR gamma-chain, and the von Willebrand factor receptor complex GPIb-IX-V, which

116 telet partners, including alphaIIbbeta3, the von Willebrand factor receptor GPIb-IX-V, the tyrosine k

117 thrombospondin motifs 13 (ADAMTS13) cleaves von Willebrand factor, reducing its prothrombotic activi

118 was deposited diffusely on capillaries, and von Willebrand factor released from endothelial cells co

119 eron-Gamma Induced Protein 10[rs4256246] and von-Willebrand-Factor[rs12829220] in the control group;

120 hase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorr

121 ety and hemostatic efficacy of a recombinant von Willebrand factor (rVWF) for treatment of bleeds in

122 and diastolic blood pressures), hemostasis (von Willebrand factor, soluble CD40 ligand, and P-select

123 was independently associated with changes in von Willebrand factor, soluble intercellular adhesion mo

124 nd -R2), endothelial injury (angiopoietin-2, von Willebrand factor, soluble thrombomodulin), impaired

125 s (fibronectin, vitronectin, collagen 1, and von Willebrand factor), strongly suggesting a role for F

126 a wide range of qualitative abnormalities of von Willebrand factor structure and function resulting i

127 blast growth factor-2), thrombosis (D-dimer, von Willebrand factor, thrombin-antithrombin III), infla

128 we evaluated transient elastography (TE) and von Willebrand factor to platelet count ratio (VITRO) as

129 Here we demonstrate that the von Willebrand factor type A (VWA) domain within the cle

130 short triple helix and consists primarily of von Willebrand factor type A (VWA) domains, protein-prot

131 aining domains of carbonic anhydrase, Sushi, Von Willebrand factor type A, and chitin binding, were i

132 Here we show that binding of its ligand, von Willebrand factor, under physiological shear stress

133 pression of endothelial cell genes including von Willebrand factor, VE-cadherin, and eNOS were observ

134 The von Willebrand factor (VWF) A1 and A3 domains are struct

135 d trigger a conformational transition in the von Willebrand factor (VWF) A2 domain, from its native f

136 Rare missense mutations in the von Willebrand factor (VWF) A3 domain that disrupt colla

137 Limited data suggest that von Willebrand factor (VWF) abnormalities may accompany

138 New options for laboratory assessment of von Willebrand factor (VWF) activity include a new plate

139 We discovered that von Willebrand factor (VWF) acts as a cofactor for facto

140 he liver, and its main function is to cleave von Willebrand factor (VWF) anchored on the endothelial

141 (WPBs), which contain the hemostatic protein von Willebrand factor (VWF) and a cocktail of angiogenic

142 VAD support causes pathologic degradation of von Willebrand factor (vWF) and bleeding from gastrointe

143 e the ER-Golgi trafficking of prohaemostatic von Willebrand factor (VWF) and extracellular matrix (EC

144 We identify reduced plasma levels of von Willebrand factor (VWF) and reduced VWF synthesis, s

145 y involving excessive endothelial-associated von Willebrand factor (VWF) and secondary platelet adhes

146 ECs synthesize both the clotting initiator von Willebrand factor (VWF) and the complement regulator

147 ow through its binding to the plasma protein von Willebrand factor (VWF) and transmits a signal into

148 To evaluate vascular cells, von Willebrand factor (vWF) and vascular endothelial gro

149 e (AVWS) secondary to a nonneutralizing anti-von Willebrand factor (VWF) antibody associated with an

150 The von Willebrand factor (vWF) antigen (vWF-Ag) correlates

151 ion coefficient adjusted for log age and log von Willebrand factor (VWF) antigen was -0.32 (P = .004)

152 lial cell and platelet activation, including von Willebrand Factor (VWF) antigen, soluble thrombomodu

153 The patients' sera were tested for von Willebrand factor (VWF) antigen, VWF collagen-bindin

154 Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) are associated with risk of

155 tween collagenous extracellular matrices and von Willebrand factor (VWF) are critical for hemostasis

156 Moreover, we found that release of von Willebrand factor (VWF) as a result of shear stress

157 ified that bind to putative phospholipid and von Willebrand factor (VWF) binding epitopes and block e

158 particular, ABO affects multiple aspects of von Willebrand factor (VWF) biology.

159 neutrophils inhibit proteolytic cleavage of von Willebrand factor (VWF) by ADAMTS13 in a concentrati

160 of the multimeric blood coagulation protein von Willebrand Factor (VWF) by ADAMTS13 is crucial for p

161 Mutations in the ultralong vascular protein von Willebrand factor (VWF) cause the common human bleed

162 the platelet GPIbalpha adhesive A1 domain of von Willebrand factor (VWF) causes quantitative VWF defi

163 Plasma factor VIII (FVIII) and von Willebrand factor (VWF) circulate together as a comp

164 Enhanced von Willebrand factor (VWF) clearance is important in th

165 loss of terminal sialic acid causes enhanced von Willebrand factor (VWF) clearance through the Ashwel

166 It is characterized by a deficiency of the von Willebrand factor (VWF) cleaving enzyme, ADAMTS13 (a

167 Von Willebrand factor (VWF) contains binding sites for p

168 Binding to the von Willebrand factor (VWF) D'D3 domains protects factor

169 iR-24), through which hyperglycemia augments von Willebrand factor (VWF) expression and secretion.

170 drophobic pocket in the central A2 domain of von Willebrand factor (VWF) for its proteolysis.

171 d that expression or infusion of a truncated von Willebrand factor (VWF) fragment containing the fact

172 pe through JAK2V617F-regulated inhibition of von Willebrand factor (VWF) function and/or secretion.

173 DAMTS13) is a metalloprotease that regulates von Willebrand factor (VWF) function.

174 The primary hemostatic von Willebrand factor (vWF) functions to sequester plate

175 ilent mutation, c.7464C>T, in exon 44 of the von Willebrand factor (VWF) gene in a family with type 1

176 Approximately 10% of von Willebrand factor (VWF) gene mutations are thought t

177 bserved for type O patients, suggesting that von Willebrand factor (VWF) half-life, as modified by th

178 von Willebrand factor (VWF) has been considered as a mar

179 Although much of the function of von Willebrand factor (VWF) has been revealed, detailed

180 ale macromolecular motions of the biopolymer von Willebrand Factor (vWF) immersed in flow.

181 An elevated level of von Willebrand factor (VWF) in diabetic patients is asso

182 nt data showing the role of platelet-derived von Willebrand factor (VWF) in mediating ischemic stroke

183 antithrombotic properties because it cleaves von Willebrand factor (VWF) in smaller, less active mult

184 otein (GP) Ib-IX-V complex, which recognizes von Willebrand factor (VWF) in the matrix.

185 gan et al have extended our understanding of von Willebrand factor (VWF) in the pathogenesis of malar

186 ke patients and found a distinct presence of von Willebrand factor (VWF) in various samples.

187 Platelet-von Willebrand factor (VWF) interactions must be tightly

188 the arterial lumen is mediated by GpIbalpha-von Willebrand Factor (VWF) interactions.

189 Von Willebrand factor (vWF) is a biomarker of endothelia

190 echano-regulation of receptor-ligand binding.Von Willebrand factor (VWF) is a blood protein involved

191 Von Willebrand factor (VWF) is a key hemostatic protein

192 Von Willebrand factor (VWF) is a key player in the regul

193 von Willebrand factor (VWF) is a large multimeric glycop

194 Von Willebrand factor (VWF) is a multimeric plasma glyco

195 von Willebrand factor (VWF) is a particularly intriguing

196 von Willebrand factor (VWF) is an essential hemostatic p

197 Activation by elongational flow of von Willebrand factor (VWF) is critical for primary hemo

198 The plasma protein von Willebrand factor (VWF) is essential for hemostasis

199 nd the release of the procoagulatory protein von Willebrand factor (VWF) is essential for malignancy,

200 Multimeric von Willebrand factor (VWF) is essential for primary hem

201 Partial quantitative deficiency of plasma von Willebrand factor (VWF) is responsible for the major

202 von Willebrand factor (VWF) laboratory testing and full-

203 es against complement C1q (Fab anti-C1q) and von Willebrand factor (VWF) led us to investigate a pote

204 iagnosis and management of patients with low von Willebrand factor (VWF) levels (30-50 IU/dL).

205 Plasma osteoprotegerin, angiopoietin-2, and von Willebrand Factor (vWF) levels were measured as biom

206 ated with an early marked increase in plasma von Willebrand factor (VWF) levels, together with a path

207 We investigated whether platelets and von Willebrand factor (VWF) mediate bacterial adhesion t

208 -terminal cystine knot (CK) (CTCK) domain in von Willebrand factor (VWF) mediates dimerization of pro

209 The blood von Willebrand factor (VWF) mediates platelet adhesion t

210 or glycoprotein Ibalpha and the A1 domain of von Willebrand factor (VWF) mediates tethering/transloca

211 have shown an intimate relationship between von Willebrand factor (VWF) multimer profile and heart v

212 Von Willebrand factor (VWF) multimer size is controlled

213 -linking during arterial thrombosis involves von Willebrand Factor (VWF) multimers.

214 nduced unraveling and elongation of tethered von Willebrand factor (VWF) multimers.

215 to signal as they tether and translocate on von Willebrand factor (VWF) of injured arterial surfaces

216 atelets from type O subjects bound poorly to von Willebrand factor (VWF) of mixed ABOs under arterial

217 This work explores the expression of von Willebrand factor (VWF) on isolated Hc resulting in

218 Glycan determinants on von Willebrand factor (VWF) play critical roles in regul

219 II), and factor VIII (FVIII) and its carrier von Willebrand factor (vWF) play key roles in hemostasis

220 Von Willebrand factor (VWF) plays a central role in hemo

221 Von Willebrand factor (VWF) plays a major role in arteri

222 The large multimeric glycoprotein von Willebrand Factor (VWF) plays a pivotal adhesive rol

223 sease (VWD) have a qualitative defect of the von Willebrand factor (VWF) protein activities.

224 O donors (n = 54) over pooled plasma derived von Willebrand factor (VWF) protein and purified blood t

225 In most patients, the von Willebrand factor (VWF) rapidly loses large multimer

226 The hemostatic protein von Willebrand factor (VWF) released by endothelial cell

227 tes along the surface of extended strings of von Willebrand factor (VWF) released from the endotheliu

228 Intriguingly, blocking von Willebrand factor (VWF) resulted in vascular leaks d

229 von Willebrand factor (vWF) secretion by endothelial cel

230 ecular techniques to dissect a mechanism for von Willebrand factor (vWF) secretion from endothelial c

231 nstrate in vitro and in an animal model that von Willebrand factor (VWF) self-association under shear

232 The large plasma glycoprotein von Willebrand factor (VWF) senses hydrodynamic forces i

233 Endogenous von Willebrand factor (VWF) stabilizes and protects FVII

234 Association with the D'D3 domain of von Willebrand factor (VWF) stabilizes factor VIII (FVII

235 von Willebrand factor (VWF) strings are removed from the

236 The von Willebrand factor (VWF) synthesized and secreted by

237 d for the large, multidomain dimeric protein von Willebrand factor (VWF) that is critically involved

238 ding is the capacity of endothelial-secreted von Willebrand factor (VWF) to assemble into thick bundl

239 The ability of von Willebrand factor (VWF) to initiate platelet adhesio

240 inase that cleaves large multimeric forms of von Willebrand factor (VWF) to smaller, less adhesive fo

241 d strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow.

242 heological shear forces in the blood trigger von Willebrand factor (VWF) unfolding which exposes the

243 The frequent von Willebrand factor (VWF) variant p.Phe2561Tyr is loca

244 els with von Willebrand disease pigs, plasma von Willebrand factor (vWF) was significantly increased

245 The metalloprotease ADAMTS13 cleaves von Willebrand factor (VWF) within endovascular platelet

246 revents microvascular thrombosis by cleaving von Willebrand factor (VWF) within platelet-rich thrombi

247 es progressed through Rab4(+), Rab11(+), and von Willebrand factor (VWF)(+) compartments in wild-type

248 Endothelial cells store von Willebrand Factor (vWF), a glycoprotein essential to

249 ponse, which in gnathostomes is regulated by von Willebrand factor (VWF), a glycoprotein that mediate

250 coagulability by affecting the production of von Willebrand factor (vWF), a key initiator of the clot

251 Von Willebrand factor (VWF), a key player in hemostasis,

252 Von Willebrand factor (VWF), a large multimeric blood pr

253 We therefore aimed to assess von Willebrand factor (vWF), a marker of endothelial dam

254 von Willebrand factor (VWF), a multimeric protein with a

255 Von Willebrand factor (VWF), an exceptionally large mult

256 ed expression levels of coagulation factors, von Willebrand factor (vWF), and tissue factor (TF), wer

257 y blockade of adhesion molecules P-selectin, von Willebrand factor (VWF), E-selectin, vascular cell a

258 We assessed von Willebrand factor (VWF), factor VIII, platelet activ

259 type I enhancer binding protein 1 (HIVEP1), von Willebrand factor (VWF), glutathione peroxidase 3 (G

260 The mechanosensitive adhesive blood protein, von Willebrand Factor (vWF), interacts with the extracel

261 e show that the endothelial-restricted gene, von Willebrand factor (VWF), is expressed in a mosaic pa

262 It's major component, the hemostatic protein von Willebrand factor (VWF), is known to assemble into l

263 binant human ADAMTS13 (rhADAMTS13), cleaving von Willebrand factor (VWF), reduces leukocyte recruitme

264 TS13 regulates blood coagulation by cleaving von Willebrand factor (VWF), reducing its procoagulant a

265 Unusually large von Willebrand factor (VWF), the first responder to vasc

266 ain the size of nanostructures ("quanta") of von Willebrand factor (vWF), the main WPB cargo.

267 xin downregulation inhibits the secretion of von Willebrand factor (VWF), the most abundant cargo in

268 ADAMTS13 metalloprotease cleaves von Willebrand factor (VWF), thereby inhibiting platelet

269 275 patients with SIRS and plasma levels of von Willebrand factor (VWF), thrombospondin-1, myelopero

270 is prevented by the multidomain glycoprotein von Willebrand factor (VWF), which binds exposed collage

271 s is caused by the functional changes of the von Willebrand Factor (VWF), which mediates coagulation

272 However, von Willebrand factor (VWF), with help from our circulat

273 D assemblies make up half of the von Willebrand factor (VWF), yet are of unknown structur

274 ytic anemia, associated with a deficiency in von Willebrand factor (VWF)-cleaving protease ADAMTS13.

275 osis defect is not related to alterations in von Willebrand factor (VWF)-GPIb adhesive function or pl

276 ADAMTS13 inhibits the growth of von Willebrand factor (VWF)-platelet aggregates by cleav

277 injury requires both factor VIII (FVIII) and von Willebrand factor (VWF).

278 signed to have a higher binding affinity for von Willebrand factor (VWF).

279 esterol levels (HDL-C and LDL-C), and plasma von Willebrand factor (vWF).

280 interaction between factor VIII (FVIII) and von Willebrand factor (VWF).

281 regulates the platelet-tethering function of von Willebrand factor (VWF).

282 orts initial platelet adhesion in absence of von Willebrand factor (VWF).

283 change in the platelet-binding A1 domain of von Willebrand factor (VWF).

284 with platelet adhesion, which is mediated by von Willebrand factor (VWF).

285 to blood vessels under shear stress requires von Willebrand factor (VWF).

286 e loss of high-molecular-weight multimers of von Willebrand factor (VWF).

287 rically regulate its proteolytic activity on von Willebrand factor (VWF).

288 ng of established EC markers VE-cadherin and von Willebrand factor (vWF).

289 blood vessel damage is highly dependent upon von Willebrand factor (VWF).

290 l-protein tyrosine phosphatase (VE-PTP), and von Willebrand factor (vWf).

291 ent therapy with desmopressin (DDAVP) and/or von Willebrand factor (VWF)/factor VIII concentrates.

292 he levels of amyloid-beta40, amyloid-beta42, von Willebrand factor (VWF; a measure of microvascular d

293 vator inhibitor type 1 [PAI-1], D-dimer, and von Willebrand factor [vWF]) were measured in plasma.

294 e rolling (P-selectin) and platelet capture (von Willebrand factor [VWF]).

295 B4, endothelial nitric oxide synthase(eNOS), von Willebrand factor(vWF), and CD31 after cardiac hyper

296 gen, type VI, alpha-3; thrombospondin 2; and von Willebrand factor) were verified by real-time polyme

297 low-serum medium showed robust secretion of von Willebrand factor when stimulated with various agoni

298 Angiopoietin-2 and von Willebrand factor, which are biomarkers of endotheli

299 ury by the acute release of the procoagulant von Willebrand factor, which is stored in unique secreto

300 ycoprotein Ib-IX-V with endothelial-released von Willebrand factor with a supporting role for the P-s